For good or for ill, the Canadian government (like many others) tightly regulates the prices that companies can charge for various drugs. And for the most part, companies have just had to take it—-putting it down to the cost of doing business in Canada. Until recently, that is.
In June, Bristol-Myers Squibb Canada announced it would not make its anti-cancer treatment Erbitux available to Canadians because it had been unable to agree on a suitable price for the drug with Canada’s Patented Medicine Prices Review Board. At the time, public relations director for BMS Canada Marc Osborne said the government’s price was “not in line with the innovation it brings to patients.”
Every now and then it helps for me to simply off-load a few random thoughts that have occurred to me over the past few months. This is one of those times.
UCSD researchers announced a new program that will see them combine their expertise in pharmaceutical sciences, medicinal chemistry and oceanography to discover and develop new antimicrobials.
Dana Farber Cancer Institute (DFCI), 454 Life Sciences and other research centers performed detailed sequencing experiments to identify subtle but significant cancer-associated mutations.
Metabolex announced a strategic agreement with Ortho-McNeil to collaborate on the development and commercialization of compounds targeting metabolic disorders.
Canadian Institute of Advanced Research (CIAR) recently announced the formation of new program that will analyze genetic networks as clues to human disease.
Data management company Unleashed Informatics recently introduced its Unleashed Global Services arm to complement its bioinformatics software and hardware offerings.
Prime Synthesis Inc. announced a new operating division, called 3-Prime LLC, intented to provide support to customers for oligonucleotide production in the research and development market.
ImmunoGen Inc. announced it grants Biotest AG exclusive rights to use ImmunoGen’s Tumor-Activated Prodrug (TAP) technology with antibodies targeting an undisclosed target to develop novel anticancer therapeutics.
Commonwealth Biotechnologies Inc. has struck a deal with PharmAust Ltd. to form a strategic alliance and client referral agreement under which they will co-market their services to the life sciences industry.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.